Kinnov Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Orleans France (2015)

Organization Overview

First Clinical Trial
2019
NCT04108104
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Kinnov Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (2)

cyproheptadine (periactin) (2 trials)

prazosin (minipress) (2 trials)

Drugs in Phase 1 Trials (1)

kt110 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3